synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
== Selecting discriminatory peptides == Finally, sophisticated normalization methods are used to remove systematic artefacts in the peptide intensity values between LC-MS measurements. Then, discriminatory peptides are identified by selecting the peptides whose normalized intensities are different (e.g., p-value < 0.05) among multiple groups of samples. In addition, newer hybrid mass spectrometers like LTQ OrbiTrap offer the possibility to acquire MS/MS peptide identifications in parallel to the high mass precision measurement of peptides on the MS1 level. This raises the computational challenge for the processing and integration of these two sources of information and has led to the development of novel promising quantification strategies.
==== Reception ==== Patrick Anderson of the Washington Post has praised McKinty as a leading light of the "new wave" of Irish crime novelists along with Ken Bruen, Declan Hughes and John Connolly. He often uses the classic noir tropes of revenge and betrayal to explore his characters' existential quest for meaning in a bleak but lyrically intense universe. Steve Dougherty writing in The Wall Street Journal praised McKinty's use of irony and humour as a counterpoint to the violent world inhabited by McKinty's Sean Duffy character. Liam McIlvanney, writing in the Irish Times, singled out McKinty's lyrical prose style as the defining characteristic of the Duffy series. Some reviewers have criticised the explicit use of violence in his novels. However, in reviewing McKinty's Fifty Grand in The Guardian, John O'Connor called him a "master craftsman of violence and redemption, up there with the likes of Dennis Lehane." His novel The Dead Yard was selected by Publishers Weekly as one of the 12 Best Novels of 2006. Audible selected Falling Glass as the Best Mystery or Thriller of 2011. In the Morning I'll Be Gone was named as one of the 10 best crime novels of 2014 by the American Library Association. In 2016, The Guardian included book 5 of the Sean Duffy series, Rain Dogs, about the investigation of a death at Carrickfergus Castle, in their "The best recent thrillers" coverage.
Vegetable soup is a common soup prepared using vegetables (including leaf vegetables, and sometimes loosely mushrooms) as primary ingredients. It dates to ancient history, and in modern times is also a mass-produced food product.
Sources: en.wikipedia.org
=== Development Tools === InSight Development Kits provide the hardware and software tools needed for application development. InSight Desktop allows for the programming and debugging of applications. It combines a packet sniffer, network analysis features, API tracing, and a virtual UART. InSight Adapter is used for network and microprocessor debugging and for programming chips. InSight USB Link is a FLASH programming device that connects to any PC via USB and to Ember’s Radio Control Module (RCM). It contains the hardware and software tools that read and write applications and program FLASH memory on the chips. AppBuilder makes network customization possible. It generates a template application that allows developers to tailor the EmberZNet PRO software to their specifications and complete the application, readying it for hardware integration and testing. It also allows configuration of the Hardware Abstraction Layer (HAL) and generates source code application with places for the developer to insert their own OEM-specific code. xIDE is a tool-chain that supports applications being written for the EM250. It has a C-language compiler, assembler, source-level debugger, and graphical editing environment.
Overview of all the structural information available in the PDB for UniProt: Q9UBU3 (Human Appetite-regulating hormone) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: Q9EQX0 (Mouse Appetite-regulating hormone) at the PDBe-KB.
=== MC1R receptor and cAMP === The melanocortin 1 receptor (MC1R) is a transmembrane and G-protein coupled receptor expressed in melanocytes. MC1R is an important target for the regulation of melanogenesis. Agonism of MC1R increases the ratio of eumelanin to pheomelanin and increases the generation of melanin overall. The MC1R and cAMP signaling pathway starts with the activation of MC1R, which causes activation of adenylyl cyclase (AC), which produces cyclic adenosine monophosphate (cAMP), which activates protein kinase A (PKA), which activates by protein phosphorylation cAMP response element-binding protein (CREB), which upregulates MITF, of which CREB is a transcription factor. Alpha-melanocyte stimulating hormone (α-MSH), beta-melanocyte stimulating hormone (β-MSH), and adrenocorticotropic hormone are endogenous agonists of MC1R. Agouti signaling protein (ASIP) appears to be the only endogenous antagonist of MC1R. Synthetic MC1R agonists have been designed, such as the peptides afamelanotide and melanotan II. Mutations of the MC1R gene correlate are at least partially responsible for red hair, white skin, and an increased risk for skin cancer in some individuals.
Attention is being turned to the still difficult, but less unpromising, problem of radio detection and numerical considerations on the method of detection by reflected radio waves will be submitted when required. The letter was discussed at the first official meeting of the Tizard Committee on 28 January 1935. The utility of the concept was evident to all attending, but the question remained whether it was actually possible. Albert Rowe and Wimperis both checked the maths and it appeared to be correct. They immediately wrote back asking for a more detailed consideration. Watt and Wilkins followed up with a 14 February secret memo entitled Detection and Location of Aircraft by Radio Means. In the new memo, Watson-Watt and Wilkins first considered various natural emanations from the aircraft – light, heat and radio waves from the engine ignition system – and demonstrated that these were too easy for the enemy to mask to a level that would be undetectable at reasonable ranges. They concluded that radio waves from their own transmitter would be needed. Wilkins gave specific calculations for the expected reflectivity of an aircraft. The received signal would be only 10−19 times as strong as the transmitted one, but such sensitivity was considered to be within the state of the art. To reach this goal, a further improvement in receiver sensitivity of two times was assumed.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.